Related Experiment Video
Updated: Apr 30, 2026

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids
Published on: April 25, 2016
Metabolic Effects of Modified-Release Hydrocortisone Versus Short Acting Conventional Oral Glucocorticoids in Adrenal
Mohammad Ehab Abdelsattar1,2, Mai Abdallah2,3, Ola Khaled2,4
1Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Objective:
Adrenal insufficiency's (AI) lifelong replacement therapy by conventional glucocorticoid (GC) regimens poorly mimics physiological cortisol, leading to poor adherence and metabolic abnormalities. Modified-release hydrocortisone (MR-HC) provides a more physiological cortisol replacement with potentially enhanced outcomes. This study assessed comparative evidence of MR-HC versus GC in patients with AI.
Design:
Systematic review and meta-analysis.
Methods:
Comparative articles published until July 2025 were searched in PubMed, Scopus and Web of Science. Glucose metabolism, anthropometrics, lipid profile and blood pressure were the primary outcomes; bone health parameters and safety and tolerability measures were secondary outcomes.
Results:
Across six included studies (n = 400), MR-HC was associated with significant reductions in BMI (mean difference -1.1, 95% CI -2.11 to -0.1) and waist circumference (-5.03, 95% CI-8.54 to -1.51), without significant changes in body weight. MR-HC lowered total cholesterol (-10.64, 95% CI -19.86 to -1.42), systolic blood pressure (-6.03, 95% CI -10.95 to -1.1) and diastolic blood pressure (-4.35, 95% CI -7.37 to -1.34). Glucose metabolic outcomes (fasting glucose and HbA1c) did not differ significantly between the groups, but sensitivity analysis suggested a potential HbA1c benefit with MR-HC. Bone health results favoured MR-HC for lumbar spine T-score (0.69, 95% CI 0.16 to 1.22), and femoral neck T-score (0.64, 95% CI 0.16 to 1.12). Safety measures favoured MR-HC for Infection score (-1.7, 95% CI -2.6 to -0.8), and flu-like events (-1.0, 95% CI -1.6 to -0.4), but not vertebral fractures (0.20, 95% CI 0.03 to 1.55), or AddiQol score (4.00, 95% CI -0.68 to 8.68).
Conclusions:
MR-HC demonstrated improved effects on anthropometric measures, lipid profile, blood pressure, bone mineral density, and safety and tolerability compared to conventional GC with no apparent differences in glucose metabolism. These findings validate MR-HC as a better regimen, but await larger long-term trials for confirmation.
Trial Registration:
This study was prospectively registered on PROSPERO (CRD420251074980). Available at: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251074980.
More Related Videos
Related Concept Videos
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Cushing Syndrome II: Pathophysiology
Cushing Syndrome I: Introduction
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Hormones of the Adrenal Glands
The adrenal cortex, a powerhouse of hormone synthesis, generates over two dozen corticosteroid hormones. The zona glomerulosa produces mineralocorticoids, exemplified by aldosterone, influencing the electrolyte composition of body fluids. The synthesis of glucocorticoids such as cortisol and...

